{"@id":"https://bioecon.ru/technology/mast-cell-targeted-therapeutics/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://cn.bioecon.ru/technology/mast-cell-targeted-therapeutics/","json":"https://cn.bioecon.ru/api/v1/technology/mast-cell-targeted-therapeutics/index.json"},"id":"mast-cell-targeted-therapeutics","industries":["pharma","biomanufacturing"],"lang":"cn","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/agc-biologics/","https://bioecon.ru/companies/newlimit/","https://bioecon.ru/companies/altos-labs/","https://bioecon.ru/companies/lonza-group/","https://bioecon.ru/companies/cellmeat/","https://bioecon.ru/companies/esco-aster/","https://bioecon.ru/companies/astrazeneca/","https://bioecon.ru/companies/hlb-genex/","https://bioecon.ru/companies/simple-planet/","https://bioecon.ru/companies/integriculture/","https://bioecon.ru/companies/cryoport-systems/"]},"maturity":7,"name":"肥大细胞靶向精准调控药物","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"抑制性受体特异性结合表位淘选"},{"n":2,"title":"非活化结合安全性确证"},{"n":3,"title":"体外脱颗粒阻断与凋亡诱导测定"},{"n":4,"title":"肥大细胞驱动性疾病体内疗效确证"}],"summary":"高选择性靶向肥大细胞表面特异性受体（如Siglec-8、MRGPRX2及c-Kit/CD117）的生物创新药，精确抑制过敏介质脱颗粒或诱导病理性肥大细胞特异性凋亡。","url":"/technology/mast-cell-targeted-therapeutics/","verified":"2026-11-22"}